Agilent Technologies Prepares to Reveal Q4 Earnings Amid Market Shifts
Agilent Technologies, Inc. (A), based in Santa Clara, California, delivers specialized solutions for the life sciences, diagnostics, and chemical sectors. With a market valuation of $38 billion, the company is known for its electronic and bio-analytical measurement tools, as well as semiconductor and board testing. Agilent, a leader in analytical and clinical laboratory technologies, is set to announce its fiscal fourth-quarter earnings for 2024 after the market closes on Monday, Nov. 25.
Expectations for Quarterly Earnings
Analysts anticipate that Agilent will report earnings of $1.41 per share on a diluted basis, reflecting a 2.2% increase from $1.38 per share in the same quarter last year. The company has a history of exceeding Wall Street’s earnings per share (EPS) estimates in its previous four quarterly reports.
Full-Year Projections
For the entire fiscal year, projections show that Agilent’s EPS will be $5.24, a decrease of 3.7% from last year’s $5.44. However, there is expected growth, with EPS projected to rise by 9.2% to $5.72 in fiscal 2025.
Stock Performance Overview
In the past year, Agilent’s stock has lagged behind the S&P 500’s impressive 38.7% growth, with its own shares rising by 25.9%. Conversely, it has outperformed the Health Care Select Sector SPDR Fund (XLV), which recorded a gain of 17.5% during the same period.
Recent Results and Analyst Outlook
On Aug. 22, Agilent’s shares rose over 2% following the release of its Q3 results. The company reported revenues of $1.58 billion, surpassing the estimate of $1.56 billion. It has since increased its full-year revenue guidance, expecting figures between $6.45 billion and $6.50 billion.
Analyst Ratings Trend
Overall, analyst sentiment toward Agilent’s stock is cautiously positive, with a “Moderate Buy” rating. Out of 16 analysts covering the stock, eight recommend a “Strong Buy,” seven suggest a “Hold,” and one advises a “Strong Sell.” The average price target for Agilent stands at $151, indicating a potential upside of 16% from current levels.
More Stock Market News from Barchart
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
